Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site. © © 2019 MORU. Photographer: Prayoon Yuentrakul.
Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site.

Coordinated by the Menzies School of Health Research (Menzies, Darwin, Australia), the Mahidol Oxford Tropical Medicine Research Unit (MORU, Bangkok, Thailand) and the Eijkman Institute of Molecular Biology (Jakarta, Indonesia), the IMPROV (Improving the Radical Cure of Vivax Malaria) trial involved > 2,000 patients in Ethiopia, Afghanistan, Indonesia and Vietnam and tested the treatment effectiveness of a high-dose 7 day course of primaquine.

Its findings challenge the standard treatment regimen that has been widely used for the last 60 years.

Read more (Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.